Sichuan Credit Pharmaceutical Co., Ltd. clinical trials
The registry lists 5 studies whose lead sponsor is Sichuan Credit Pharmaceutical Co., Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 3, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 5studies on the registry
- 5open to participants now
- 2reach primary completion within a year
Get an email when these change. Save the Sichuan Credit Pharmaceutical Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 1 programme
Each counted once: 1 with a study Sichuan Credit Pharmaceutical Co., Ltd. leads registered in the last two years.
- Phase 1
The 1 programme — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
“Registry” is the highest phase of Sichuan Credit Pharmaceutical Co., Ltd.’s own registered studies; Sichuan Credit Pharmaceutical Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Sichuan Credit Pharmaceutical Co., Ltd.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
2 of Sichuan Credit Pharmaceutical Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- 1OOct
- NNov
All 2
- Jan 2027Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.NCT07645807
- Oct 2027A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent StudyNCT07893002
Add all 2 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 15, 2026.
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now5100%Not yet recruiting 3 · Enrolling by invitation 1 · Recruiting 1
Where
- India5
Over the years
- 25
- 426
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sichuan Credit Pharmaceutical Co., Ltd..
- Sichuan Credit Pharmaceutical Co., Ltd.5 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 5 of 5.
- A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent StudyRecruitingNCT07893002Not applicable
- To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting ConditionsNot yet recruitingNCT07664657Not applicable
- Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.Not yet recruitingNCT07645807Not applicable
- Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting ConditionsNot yet recruitingNCT07461649Not applicable
- CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting ConditionsEnrolling by invitationNCT06758778Not applicable